Ennaid Therapeutics | Ennaid Therapeutics Announces Development of ENU200, A New Antiviral Therapeutic for the Treatment of COVID-19
19514
post-template-default,single,single-post,postid-19514,single-format-standard,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-6.2.0,vc_non_responsive

Ennaid Therapeutics Announces Development of ENU200, A New Antiviral Therapeutic for the Treatment of COVID-19

02 Apr Ennaid Therapeutics Announces Development of ENU200, A New Antiviral Therapeutic for the Treatment of COVID-19

ENU200 has demonstrated specific antiviral activity against two SARS-CoV-2 proteins, S glycoprotein and Mpro

ALPHARETTA, Ga., April 2, 2020 /PRNewswire/ — Ennaid Therapeutics, LLC, a specialty pharmaceutical company that uses its artificial intelligence (AI)-based drug discovery platforms to develop antiviral drugs, today announced that it is advancing the development of ENU200, as a therapeutic to treat the up to 80% of asymptomatic, mild to moderate cases of COVID-19 viral infections. 

ENU200 is a repurposed, patent-pending, orally deliverable antiviral drug that was previously approved by the U.S. Food and Drug Administration (FDA) for a different indication. In-silico modeling conducted by Ennaid has revealed that ENU200 delivers specific antiviral activity against two SARS-CoV-2 proteins, S glycoprotein and Mpro. Ennaid’s science suggests that this simultaneous blockage may result in enhanced antiviral activity that could successfully and broadly treat COVID-19 and other coronaviruses (CoVs).

Darnisha Harrison, Founder and CEO at Ennaid Therapeutics, said, “Our science strongly suggests that ENU200, a repurposed drug with a well-established clinical and safety profile, has the potential to be a broad solution to address the COVID-19 pandemic and, specifically, the near 80 percent of coronavirus cases that are asymptomatic, mild to moderate. Key to ENU200 is its target of two proteins on the SARS-CoV-2 virus that interfere with the virus’ ability to enter healthy cells and its replication. Additionally, unlike other COVID-19 drugs in development, which must be administered via injection or intravenously under the care of a physician, ENU200 can be administered orally, thus enabling in-home treatment for COVID-19 infections.”

Read the rest of the article HERE.

No Comments

Post A Comment